Hermilito L. Villar

Hermilito Villar practices at Perpetual Medical Group in Granada Hills, California.

Hermilito Villar's NPI, 1710946009, was assigned on March 23, 2006. Hermilito Villar holds California license A41795.

Hermilito Villar's primary practice is Perpetual Medical Group, at 17050 W Chatsworth St, Granada Hills, CA 91344 in Los Angeles County. The practice phone is (747) 300-7541.

Hermilito Villar's primary practice is Perpetual Medical Group in Granada Hills, California. Dmand AI also links Hermilito Villar to 5 home health agencies and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Hermilito Villar practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Hermilito Villar's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Hermilito Villar is licensed in California.

CMS data shows 22,791 Medicare services from Hermilito Villar across 27 procedure codes in 2024, for 2,499 Medicare patients. Medicare paid $1,759,649 for them. Every service was in an office.

CMS counts 2,499 Medicare patients who saw Hermilito Villar in 2024. The largest group is 65 to 74, with 1,117 patients. 75% of them have arthritis, and 75% have high blood pressure. 89% are also on Medicaid. Their average risk score is 1.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Hermilito Villar's median patient age at 74, with 59% women.

In 2024, Hermilito Villar wrote 7,366 Medicare Part D claims for 507 patients. 85% of them were for generic drugs. CMS names the drug for 6,667 of them, across 105 drugs with 11 or more claims each, at $666,667 in total drug cost. In 2023, CMS named 7,290 claims across 117 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Hermilito Villar for performance year 2024, reported individually. Hermilito Villar accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Hermilito Villar to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Ectoparasitic Infestations and Mite Infestations.

CMS Open Payments shows 214 general payments to Hermilito Villar from 22 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,649.